What is the debt of Oxford Biomedica this year?
Oxford Biomedica has a debt level of 7.74 GBP this year.
Oxford Biomedica Debt 2024
Oxford Biomedica Debt
7.74 GBP
Oxford Biomedica Dividend yield
Ticker
OXB.L
ISIN
GB00BDFBVT43
WKN
A2JLRX
In 2024, Oxford Biomedica's total debt was 7.74 GBP, a -104.6% change from the -168.28 GBP total debt recorded in the previous year.
Oxford Biomedica Aktienanalyse
What does Oxford Biomedica do?
Oxford BioMedica PLC is a biopharmaceutical company based in Oxford, England. The company was founded in 1995 and has since become a leading provider of gene therapy products. The company's business model is to develop, produce, and market gene therapies for rare diseases and cancer. Oxford BioMedica utilizes modern technologies, such as viral vectors, to introduce genetic material into diseased cells and correct their function. One of the company's main areas of focus is the development of gene therapies for rare diseases. Oxford BioMedica has several promising products in this field, including gene therapies for metabolic disorders, muscular diseases, and eye diseases. Another important area for the company is the development of cancer immunotherapies. Oxford BioMedica is working on the development of gene therapies that activate the body's immune system to specifically target cancer cells. Among the products that Oxford BioMedica has already brought to market is the gene therapy product Strimvelis, which is used to treat severe combined immunodeficiency (SCID). Through treatment with Strimvelis, children with SCID can lead a normal life and are no longer confined to sterile environments. Another well-known product from Oxford BioMedica is the gene therapy product OXB-102, which is being tested in phase III clinical trials for the treatment of Parkinson's disease. In this therapy, a viral vector is used to correct a genetic mutation in the affected brain cells and alleviate the symptoms of Parkinson's. In recent years, Oxford BioMedica has also formed significant partnerships with major pharmaceutical and biotech companies such as Novartis, Sanofi, and Bioverativ to further develop and bring its gene therapy technology and products to market. Overall, Oxford BioMedica is a leading company in the field of gene therapy. With a strong pipeline of promising products and significant partnerships with the pharmaceutical industry, the company is well positioned to continue growing and contribute to the cure of diseases. Oxford Biomedica ist eines der beliebtesten Unternehmen auf Eulerpool.com.Debt Details
Understanding Oxford Biomedica's Debt Structure
Oxford Biomedica's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.
Year-to-Year Comparison
Analyzing Oxford Biomedica's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.
Impact on Investments
Investors pay close attention to Oxford Biomedica’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.
Interpreting Debt Fluctuations
Shifts in Oxford Biomedica’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.
Frequently Asked Questions about Oxford Biomedica Stock
What was the debt of Oxford Biomedica compared to the previous year?
The debt of Oxford Biomedica has increased by -104.6% compared to the previous year dropped.
What are the consequences of high debt for investors in Oxford Biomedica?
High debt can pose a risk for investors of Oxford Biomedica, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.
What are the consequences of low debt for investors of Oxford Biomedica?
Low debt means that Oxford Biomedica has a strong financial position and is able to fulfill its obligations without overburdening its finances.
How does an increase in debt from Oxford Biomedica affect the company?
An increase in debt of Oxford Biomedica can adversely affect the financial condition of the company and result in a higher burden on its finances.
How does a reduction of debt of Oxford Biomedica affect the company?
A reduction in debt of Oxford Biomedica can strengthen the company's financial position and improve its ability to meet its financial obligations.
What are some factors that influence the debt of Oxford Biomedica?
Some factors that can influence the debt of Oxford Biomedica include investments, acquisitions, operating costs, and revenue development.
Why are the debts of Oxford Biomedica so important for investors?
The debts of Oxford Biomedica are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.
What strategic measures can Oxford Biomedica take to change the debt?
To change the debt, Oxford Biomedica can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.
How much dividend does Oxford Biomedica pay?
Over the past 12 months, Oxford Biomedica paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Oxford Biomedica is expected to pay a dividend of 0 GBP.
What is the dividend yield of Oxford Biomedica?
The current dividend yield of Oxford Biomedica is .
When does Oxford Biomedica pay dividends?
Oxford Biomedica pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Oxford Biomedica?
Oxford Biomedica paid dividends every year for the past 0 years.
What is the dividend of Oxford Biomedica?
For the upcoming 12 months, dividends amounting to 0 GBP are expected. This corresponds to a dividend yield of 0 %.
In which sector is Oxford Biomedica located?
Oxford Biomedica is assigned to the 'Health' sector.
Wann musste ich die Aktien von Oxford Biomedica kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Oxford Biomedica from 5/28/2024 amounting to 0 GBP, you needed to have the stock in your portfolio before the ex-date on 5/28/2024.
When did Oxford Biomedica pay the last dividend?
The last dividend was paid out on 5/28/2024.
What was the dividend of Oxford Biomedica in the year 2023?
In the year 2023, Oxford Biomedica distributed 0 GBP as dividends.
In which currency does Oxford Biomedica pay out the dividend?
The dividends of Oxford Biomedica are distributed in GBP.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The Oxford Biomedica stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von Oxford Biomedica
Our stock analysis for Oxford Biomedica Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Oxford Biomedica Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
- Oxford Biomedica Revenue
- Oxford Biomedica Net Income
- Oxford Biomedica P/E
- Oxford Biomedica P/S
- Oxford Biomedica EBIT
- Oxford Biomedica Dividend
- Oxford Biomedica Stocks
- Oxford Biomedica Market capitalization
- Oxford Biomedica Debt
- Oxford Biomedica Liabilities
- Oxford Biomedica Equity
- Oxford Biomedica AAQS
- Oxford Biomedica Employees
- Oxford Biomedica ROE
- Oxford Biomedica ROA
- Oxford Biomedica ROCE
